Page last updated: 2024-08-25

rosiglitazone and Diabetic Nephropathies

rosiglitazone has been researched along with Diabetic Nephropathies in 51 studies

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (47.06)	29.6817
2010's	21 (41.18)	24.3611
2020's	6 (11.76)	2.80

Authors

Authors	Studies
Kong, WJ; Li, YH; Niu, TY; Pang, YD; Song, DQ; Tang, S; Wang, C; Wang, YX; Zhang, YH	1
Gu, YH; Hou, DL; Li, HB; Liu, K; Qi, X; Xu, QL; Zhao, X	1
Gu, H; Xu, J; Zheng, F	1
Chen, N; Liu, J; Liu, Y; Wang, W; Yu, X; Zhang, L; Zhou, F; Zhou, Y; Zhu, Y	1
Alawi, LF; Chodavarapu, H; El-Amouri, SS; Elased, KM; Emberesh, SE; Fadnavis, R; Owuor, BA	1
Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM	1
Baker, HE; Breyer, MD; Cramer, MS; Harlan, SM; Heinz-Taheny, KM; Heuer, JG; Jaqua, DL; Qi, Z; Shiyanova, TL; Sullivan, JM; Wei, T	1
Chen, N; Liu, J; Wang, W; Zhang, L; Zhou, F	1
Chen, LJ; Cheng, JT; Cherng, YG; Hsu, CT; Huang, KC	1
Emmett, N; Leander, M; Li, L; Wang, G; Zhang, Y; Zhao, X	1
Ahad, A; Ahsan, H; Mujeeb, M; Siddiqui, WA	1
Gad, HI	1
Feng, Y; Shi, LL; Wang, LY; Wang, Y; Xu, JW	1
Brosius, FC; Byun, J; Feldman, EL; Kennedy, RT; Kretzler, M; Lorenz, M; Pennathur, S; Saha, J; Schin, M; Zhang, H	1
Bierhaus, A; Bozorgmehr, F; Dugi, K; Hamann, A; Humpert, PM; Ibrahim, Y; Kientsch-Engels, R; Kukudov, G; Morcos, M; Nawroth, PP; Oikomonou, D; Pfisterer, F; Rudofsky, G; Sayed, AA; Schlotterer, A; Schneider, J; Schwenger, V; van der Woude, F; Yard, B; Zeier, M	1
Kumar, H; Mishra, M; Tripathi, K; Vijay, SK	1
Chen, K; Chen, Y; Li, S; Qian, Y; Yang, G; Ye, S; Zhai, Z	1
Albert, JM; Bailie, GR; Blayney, MJ; Goodkin, DA; Pisoni, RL; Port, FK; Ramirez, SP; Tentori, F; Wolfe, RA; Young, EW	1
Ahn, YB; Baek, KH; Kang, MI; Kim, MK; Ko, SH; Lee, KW; Song, KH; Yoon, KH	1
Andresen, BT; Lu, N; Trivedi, H; Whaley-Connell, A	1
Booth, A; Konstantinidis, A; Lambley, RG; Vahdani, K	1
Burt, D; Camussi, G; Gruden, G; Miceli, I; Perin, PC; Tarabra, E	1
Bob, F; Bozdog, G; Dragos Jianu, C; Dumitrascu, V; Gadalean, F; Giju, S; Gluhovschi, C; Gluhovschi, G; Ianculescu, C; Marian, R; Petrica, L; Petrica, M; Ursoniu, S; Velciov, S; Vlad, A	1
Georgianos, PI; Lasaridis, AN; Sarafidis, PA; Saratzis, AN; Stafylas, PC	1
Arora, MK; Balakumar, P; Reddy, K	1
Cruzado, JM; Flaquer, M; Franquesa, M; Grinyó, JM; Herrero-Fresneda, I; Lloberas, N; Rosa, JL; Torras, J; Vidal, A	1
Chan, LY; Cheng, AS; Lai, KN; Lan, HY; Leung, JC; Tang, SC	1
Barone, F; Bilous, R; Buckingham, R; Dessapt, C; Gnudi, L; Gruden, G; Hayward, A; Hiroshi, K; Setti, G; Viberti, G; White, K	1
Aftring, RP; Haffner, SM; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Paul, G; Viberti, G; Zinman, B	1
Bastacky, S; Bilan, VP; Jones, HB; Mayers, RM; Poucher, SM; Salah, EM; Tofovic, SP; Zinker, B	1
Abd el-Latif, FF; Khalifa, M; Sayed, AA	1
Greevy, RA; Griffin, MR; Grijalva, CG; Hung, AM; Ikizler, TA; Liu, X; Murff, HJ; Roumie, CL	1
Ao, X; Hou, Q; Li, G; Zhang, Y	1
Hu, W; Liu, D; Yu, Q; Zhang, J	1
Kouroumichakis, I; Liakopoulos, V; Maltezos, E; Mikhailidis, DP; Papanas, N; Zarogoulidis, P	1
Bornstein, SR; Gross, P; Herbrig, K; Passauer, J; Pistrosch, F; Schwanebeck, U	1
Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM	1
Grossman, E	1
Chan, JC; Chan, NN; Chiu, CK; Leung, WY; So, WY; Tong, PC	1
Fischer, S; Gross, P; Herbrig, K; Kindel, B; Passauer, J; Pistrosch, F	1
Chan, LY; Lai, KN; Leung, JC; Tang, SC; Tsang, AW	1
Allen, TJ; Calkin, AC; Cooper, ME; Giunti, S; Jandeleit-Dahm, KA; Thomas, MC	1
Bakris, GL; Sarafidis, PA	1
Chiang, CK; Ho, TI; Hsu, SP; Hung, KY; Pai, MF; Peng, YS; Wu, KD; Yang, SY	1
Cho, BP; Chung, CH; Koh, JH; Lee, BJ; Lee, EY; Lee, MY; Shin, JY; Shin, YG; Won, CS	1
Bao, Y; Jia, RH; Li, J; Yuan, J	1
Cersosimo, E; DeFronzo, RA; Miyazaki, Y; Triplitt, C	1
Gilbert, RE	1
Guan, Y; Zheng, F	1
Bégaud, B; Bernard, MH; Eschwège, E; Grimaldi, A; Oppert, JM; Pouchain, D; Slama, G	1
Collins, AR; Hsueh, WA; Kawano, Y; Nicholas, SB; Wakino, S	1

Reviews

4 review(s) available for rosiglitazone and Diabetic Nephropathies

Article	Year
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010, Volume: 55, Issue:5 Topics: Albuminuria; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; PPAR gamma; Proteinuria; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones	2010
Fibrates: therapeutic potential for diabetic nephropathy? European journal of internal medicine, 2012, Volume: 23, Issue:4 Topics: Animals; Creatinine; Diabetic Nephropathies; Disease Progression; Fenofibrate; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; PPAR alpha; Rosiglitazone; Thiazolidinediones	2012
Rosiglitazone reduces blood pressure and urinary albumin excretion in type 2 diabetes: G Bakris et al. Journal of human hypertension, 2003, Volume: 17, Issue:1 Topics: Albuminuria; Blood Pressure Determination; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Prognosis; Risk Assessment; Risk Factors; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones	2003
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney international, 2006, Volume: 70, Issue:7 Topics: Albuminuria; Animals; Blood Pressure; Chromans; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Humans; Hypoglycemic Agents; Kidney; Kidney Failure, Chronic; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Rosiglitazone; Thiazolidinediones; Time Factors; Troglitazone	2006

Trials

10 trial(s) available for rosiglitazone and Diabetic Nephropathies

Article	Year
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study. Pediatric diabetes, 2020, Volume: 21, Issue:6 Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Male; Metformin; Risk Reduction Behavior; Rosiglitazone	2020
Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta diabetologica, 2009, Volume: 46, Issue:1 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Neovascularization, Pathologic; Patient Selection; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones; Triglycerides; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A	2009
Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:23-24 Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Neuroprotective Agents; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2009
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:5 Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2011
[Puerarin combined with avandia for diabetic nephropathy]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2012, Volume: 37, Issue:1 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Isoflavones; Male; Middle Aged; Rosiglitazone; Thiazolidinediones	2012
Effect of thiazolidinedione treatment on proteinuria and renal hemodynamic in type 2 diabetic patients with overt nephropathy. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2012, Volume: 44, Issue:12 Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Pilot Projects; PPAR gamma; Proteinuria; Renal Circulation; Rosiglitazone; Severity of Illness Index; Thiazolidinediones	2012
Rosiglitazone reduces urinary albumin excretion in type II diabetes. Journal of human hypertension, 2003, Volume: 17, Issue:1 Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome	2003
Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes, 2005, Volume: 54, Issue:7 Topics: Aged; Albuminuria; Cross-Over Studies; Diabetic Nephropathies; Double-Blind Method; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Male; Middle Aged; Placebos; Rosiglitazone; Thiazolidinediones	2005
Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes care, 2007, Volume: 30, Issue:1 Topics: C-Reactive Protein; Cohort Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver Function Tests; Male; Middle Aged; Prospective Studies; Renal Dialysis; Rosiglitazone; Safety; Thiazolidinediones; Virus Diseases	2007
Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney international, 2007, Volume: 72, Issue:11 Topics: Adiponectin; Albuminuria; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Double-Blind Method; Fatty Acids, Nonesterified; Glucose; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Linear Models; Middle Aged; Multivariate Analysis; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2007

Other Studies

37 other study(ies) available for rosiglitazone and Diabetic Nephropathies

Article	Year
Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy. European journal of medicinal chemistry, 2020, Sep-01, Volume: 201 Topics: Alkaloids; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Hep G2 Cells; Humans; Hypoglycemic Agents; Kidney; Male; Matrines; Mice, Inbred C57BL; Molecular Structure; Pancreas; Quinolizines; Structure-Activity Relationship	2020
Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms. European journal of medicinal chemistry, 2021, Jun-05, Volume: 218 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypoglycemic Agents; Male; Molecular Structure; NF-kappa B; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Streptozocin; Structure-Activity Relationship	2021
Focal Microscopy Observe the Mechanism of Gegen Qinlian Decoction Treating Type 2 Diabetic Nephropathy in Nude Mice. BioMed research international, 2022, Volume: 2022 Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drugs, Chinese Herbal; Mice; Mice, Nude; Microscopy; Rosiglitazone	2022
Altered Expression of Long Noncoding and Messenger RNAs in Diabetic Nephropathy following Treatment with Rosiglitazone. BioMed research international, 2020, Volume: 2020 Topics: Animals; Computational Biology; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; NF-kappa B; PPAR gamma; RNA, Long Noncoding; RNA, Messenger; Rosiglitazone; Sequence Analysis, RNA; Tumor Necrosis Factor-alpha; Up-Regulation	2020
Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice. Physiological reports, 2020, Volume: 8, Issue:3 Topics: Animals; Diabetic Nephropathies; Down-Regulation; Hyperglycemia; Hypoglycemic Agents; Kidney; Male; Mice; Neprilysin; Rosiglitazone	2020
Progressive Renal Disease Established by Renin-Coding Adeno-Associated Virus-Driven Hypertension in Diverse Diabetic Models. Journal of the American Society of Nephrology : JASN, 2018, Volume: 29, Issue:2 Topics: Animals; Antihypertensive Agents; Creatinine; Dependovirus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Female; Genetic Vectors; Hypertension; Hypoglycemic Agents; Janus Kinases; Lac Operon; Lisinopril; Male; Mice; Nephrectomy; Nitric Oxide Synthase Type III; Renin; Rosiglitazone; Serum Albumin; Severity of Illness Index; Signal Transduction; STAT Transcription Factors	2018
PGC-1α ameliorates kidney fibrosis in mice with diabetic kidney disease through an antioxidative mechanism. Molecular medicine reports, 2018, Volume: 17, Issue:3 Topics: Animals; Cell Line; Diabetic Nephropathies; Fibrosis; Kidney; Mesangial Cells; Mice; Mice, Inbred C57BL; Mitochondria; Nuclear Respiratory Factor 1; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Podocytes; PPAR gamma; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Rosiglitazone; Serum Albumin; Superoxide Dismutase; Thiazolidinediones; Up-Regulation	2018
Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2014, Volume: 46, Issue:4 Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Glucuronidase; Kidney; Klotho Proteins; Male; PPAR gamma; Rats, Wistar; Receptor, Fibroblast Growth Factor, Type 1; Rosiglitazone; Thiazolidinediones	2014
Altered expression profile of renal α(1D)-adrenergic receptor in diabetes and its modulation by PPAR agonists. Journal of diabetes research, 2014, Volume: 2014 Topics: Animals; Cell Dedifferentiation; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Gene Expression Profiling; Hypoglycemic Agents; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Obesity; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Receptors, Adrenergic, alpha-1; Rosiglitazone; Thiazolidinediones; Up-Regulation	2014
Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats. Biochimie, 2014, Volume: 106 Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Blood Glucose; Blotting, Western; Body Weight; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Eating; Flavanones; Hypoglycemic Agents; Kidney; Male; NF-kappa B; Nitric Oxide Synthase Type II; Rats, Wistar; Rosiglitazone; Streptozocin; Thiazolidinediones; Transforming Growth Factor beta1; Treatment Outcome	2014
Does combined peroxisome proliferator-activated receptors-agonist and pravastatin therapy attenuate the onset of diabetes-induced experimental nephropathy? Saudi medical journal, 2014, Volume: 35, Issue:11 Topics: Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycated Hemoglobin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Kidney; Lipid Peroxides; Peroxisome Proliferator-Activated Receptors; Pravastatin; Rats; Rosiglitazone; Thiazolidinediones; Transferrin; Tumor Necrosis Factor-alpha	2014
Protective Effects of MDG-1, a Polysaccharide from Ophiopogon japonicus on Diabetic Nephropathy in Diabetic KKAy Mice. International journal of molecular sciences, 2015, Sep-17, Volume: 16, Issue:9 Topics: Administration, Oral; Animals; Blood Glucose; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Administration Schedule; Gene Expression Regulation; Hypoglycemic Agents; Kidney; Mice; Polysaccharides; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Triglycerides	2015
Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. American journal of physiology. Renal physiology, 2008, Volume: 295, Issue:4 Topics: Albuminuria; Animals; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Male; Mice; Mice, Inbred DBA; Oxidative Stress; Podocytes; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Thiazolidinediones; Urine	2008
Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2008, Volume: 40, Issue:11 Topics: Angiotensin II; Cell Nucleus; Cells, Cultured; Diabetic Nephropathies; Epithelial Cells; Gene Expression; Glycation End Products, Advanced; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; NF-kappa B; Oxidative Stress; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rosiglitazone; Thiazolidinediones; Tyrosine	2008
Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats. Journal of endocrinological investigation, 2008, Volume: 31, Issue:12 Topics: Animals; Cytoprotection; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Drug Evaluation, Preclinical; Gene Expression Regulation; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Kidney; Male; Rats; Rats, Wistar; RNA, Messenger; Rosiglitazone; Streptozocin; Thiazolidinediones	2008
Rosiglitazone is associated with mortality in chronic hemodialysis patients. Journal of the American Society of Nephrology : JASN, 2009, Volume: 20, Issue:5 Topics: Aged; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Female; Hospitalization; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Renal Dialysis; Rosiglitazone; Thiazolidinediones	2009
Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. The Korean journal of internal medicine, 2009, Volume: 24, Issue:3 Topics: Adult; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2009
Slower decline of renal function after initiation of rosiglitazone in diabetics -- a pilot study. Clinical nephrology, 2009, Volume: 72, Issue:3 Topics: Aged; Diabetic Nephropathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Male; Pilot Projects; Renal Insufficiency; Rosiglitazone; Thiazolidinediones; Time Factors	2009
Rosiglitazone and pioglitazone. Beware macular oedema. BMJ (Clinical research ed.), 2009, Sep-22, Volume: 339 Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular Edema; Pioglitazone; Rosiglitazone; Thiazolidinediones	2009
Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cell Proliferation; Cells, Cultured; Diabetic Nephropathies; Down-Regulation; Humans; Membrane Proteins; Podocytes; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Rosiglitazone; Stress, Mechanical; Thiazolidinediones; Up-Regulation	2010
The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. European journal of pharmacology, 2010, Jun-25, Volume: 636, Issue:1-3 Topics: Animals; Blood Glucose; Blood Urea Nitrogen; Creatinine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Interactions; Fenofibrate; Kidney; Lipids; Oxidative Stress; PPAR alpha; PPAR gamma; Proteinuria; Rats; Rosiglitazone; Thiazolidinediones	2010
The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats. Life sciences, 2010, Jul-31, Volume: 87, Issue:5-6 Topics: Albuminuria; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Hypoglycemic Agents; Immunosuppressive Agents; Male; Protein Phosphatase 2; Rats; Rats, Sprague-Dawley; Rosiglitazone; Sirolimus; Thiazolidinediones; Transcription Factors; Transforming Growth Factor beta1	2010
Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: Role of STAT1 inhibition and nephrin restoration. American journal of nephrology, 2010, Volume: 32, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Kidney; Kidney Glomerulus; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Nephrectomy; Protective Agents; Rosiglitazone; STAT1 Transcription Factor; Thiazolidinediones	2010
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. American journal of nephrology, 2010, Volume: 32, Issue:5 Topics: Albuminuria; Animals; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Kidney; Macrophages; Male; Membrane Proteins; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones	2010
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. The Journal of endocrinology, 2011, Volume: 210, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Enalapril; Humans; Hypoglycemic Agents; Kidney; Liver; Male; Metabolic Syndrome; Myocardium; Obesity; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones	2011
Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats. Journal of physiology and biochemistry, 2012, Volume: 68, Issue:2 Topics: Alloxan; Animals; Anti-Inflammatory Agents; Antioxidants; Catalase; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glutathione; Interleukin-6; Kidney; Lipid Peroxidation; Malondialdehyde; Metformin; Oxidative Stress; Phytotherapy; Plant Extracts; Rats; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones; Trigonella	2012
Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney international, 2012, Volume: 81, Issue:7 Topics: Administration, Oral; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome	2012
Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats. Inflammation, 2012, Volume: 35, Issue:4 Topics: Adipokines; Animals; Blood Glucose; Body Weight; Chemokines; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Intercellular Adhesion Molecule-1; Intercellular Signaling Peptides and Proteins; Kidney; Male; Pioglitazone; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Chemokine; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2012
The metabolic effects of insulin and rosiglitazone combination therapy in Chinese type 2 diabetic patients with nephropathy. Medical science monitor : international medical journal of experimental and clinical research, 2004, Volume: 10, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Hemoglobin A; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Rosiglitazone; Thiazolidinediones; Time Factors	2004
Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:6 Topics: Cell Line; Diabetic Nephropathies; Enzyme Inhibitors; Epithelial Cells; Humans; Immunohistochemistry; Interleukin-8; Kidney; MAP Kinase Signaling System; NF-kappa B; PPAR gamma; RNA, Messenger; Rosiglitazone; Signal Transduction; STAT1 Transcription Factor; Thiazolidinediones	2006
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:9 Topics: Animals; Apolipoproteins E; Collagen Type IV; Creatinine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Gemfibrozil; Hypoglycemic Agents; Hypolipidemic Agents; Male; Mice; Mice, Knockout; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones	2006
Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats. Yonsei medical journal, 2007, Apr-30, Volume: 48, Issue:2 Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Male; Pioglitazone; Rats; Rats, Long-Evans; Rosiglitazone; Thiazolidinediones; Vascular Endothelial Growth Factor A	2007
Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology, 2007, Volume: 80, Issue:1 Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Male; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosiglitazone; Thiazolidinediones	2007
Rosiglitazone: opening Pandora's black box? Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:6 Topics: Diabetic Nephropathies; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Thiazolidinediones	2007
Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Kidney international, 2007, Volume: 72, Issue:11 Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucose; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones	2007
[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study]. Annales d'endocrinologie, 2008, Volume: 69, Issue:1 Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors	2008
Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells. Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2 Topics: Animals; Cell Nucleus; Cells, Cultured; Chromans; Cytoplasm; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Fibrinolysin; Glomerular Mesangium; Matrix Metalloproteinase Inhibitors; Plasminogen Activator Inhibitor 1; Platelet-Derived Growth Factor; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone	2001